Imperial College London

Professor Paul M. Matthews

Faculty of MedicineDepartment of Brain Sciences

Edmond and Lily Safra Chair. Head of Department
 
 
 
//

Contact

 

+44 (0)20 7594 2855p.matthews

 
 
//

Assistant

 

Ms Siobhan Dillon +44 (0)20 7594 2855

 
//

Location

 

E502Burlington DanesHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Stangel:2017:10.1038/nrneurol.2017.139,
author = {Stangel, M and Kuhlmann, T and Matthews, PM and Kilpatrick, TJ},
doi = {10.1038/nrneurol.2017.139},
journal = {Nature Reviews Neurology},
pages = {742--754},
title = {Achievements and obstacles of remyelinating therapies in multiple sclerosis},
url = {http://dx.doi.org/10.1038/nrneurol.2017.139},
volume = {13},
year = {2017}
}

RIS format (EndNote, RefMan)

TY  - JOUR
AB - Remyelination in the CNS is the natural process of damage repair in demyelinating diseases such as multiple sclerosis (MS). However, remyelination becomes inadequate in many people with MS, which results in axonal degeneration and clinical disability. Enhancement of remyelination is a logical therapeutic goal; nevertheless, all currently licensed therapies for MS are immunomodulatory and do not support remyelination directly. Several molecular pathways have been identified as potential therapeutic targets to induce remyelination, and some of these have now been assessed in proof-of-concept clinical trials. However, trial design faces several obstacles: optimal clinical or paraclinical outcome measures to assess remyelination remain ill-defined, and identification of the ideal timing of therapy is also a crucial issue. In addition, realistic expectations are needed concerning the probable benefits of such therapies. Nevertheless, approaches that enhance remyelination are likely to be protective for axons and so could prevent long-term neurodegeneration. Future MS treatment paradigms, therefore, are likely to comprise a combinatorial approach that involves both immunomodulatory and regenerative treatments.
AU - Stangel,M
AU - Kuhlmann,T
AU - Matthews,PM
AU - Kilpatrick,TJ
DO - 10.1038/nrneurol.2017.139
EP - 754
PY - 2017///
SN - 1759-4758
SP - 742
TI - Achievements and obstacles of remyelinating therapies in multiple sclerosis
T2 - Nature Reviews Neurology
UR - http://dx.doi.org/10.1038/nrneurol.2017.139
UR - http://hdl.handle.net/10044/1/56018
VL - 13
ER -